Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158156040> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2158156040 endingPage "305" @default.
- W2158156040 startingPage "301" @default.
- W2158156040 abstract "To asses the efficacy and safety of Topiglan (1% alprostadil in a formulation with 5% SEPA [soft enhancer of percutaneous absorption]) or placebo gel (0.25 mL) applied to the glans penis only in 60 patients with moderate to severe erectile dysfunction in a two-visit, in-office clinical trial.During the first visit, open-label placebo gel was applied. At the second visit, blind, random allocation to Topiglan (n = 31) or placebo gel (n = 29) occurred. Thirty minutes after application, an erotic movie showing heterosexual sex began; at 45 minutes, a penile vibrator was used. Audiovisual and tactile stimulation were discontinued at 65 minutes, and the patient was observed until 90 minutes after application. At the scheduled time points, the erection response was assessed by both the investigator and the patient and signs and symptoms of tolerance were evaluated.Topiglan produced a greater angle of erection (P = 0.003) and maximum rigidity (P = 0.033) compared with the placebo gel. The responses to Topiglan were greater than to placebo gel at all time points after application, with the greatest differences observed at 45 and 60 minutes. Of the 31 patients treated with Topiglan, 12 (38.9%) achieved an erection judged sufficient for vaginal penetration (P = 0.005); 2 (6.9%) of the 29 patients who received placebo gel did so. Penile erythema was more common with Topiglan; symptoms of minor to mild warmth or burning and, less commonly, tingling and coolness were reported by most patients after both Topiglan and placebo gel application. No significant changes in vital signs were noted.Topiglan applied to the glans penis increased penile rigidity and expectations regarding vaginal penetration in patients with erectile dysfunction." @default.
- W2158156040 created "2016-06-24" @default.
- W2158156040 creator A5007803051 @default.
- W2158156040 creator A5075242001 @default.
- W2158156040 creator A5083235376 @default.
- W2158156040 date "2001-02-01" @default.
- W2158156040 modified "2023-09-26" @default.
- W2158156040 title "A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction" @default.
- W2158156040 cites W178298697 @default.
- W2158156040 cites W1909097275 @default.
- W2158156040 cites W1965483911 @default.
- W2158156040 cites W1970051466 @default.
- W2158156040 cites W1992898085 @default.
- W2158156040 cites W2009511893 @default.
- W2158156040 cites W2157388128 @default.
- W2158156040 cites W2167833794 @default.
- W2158156040 cites W2312845168 @default.
- W2158156040 cites W2398826184 @default.
- W2158156040 cites W24650497 @default.
- W2158156040 cites W2499235892 @default.
- W2158156040 cites W2912531091 @default.
- W2158156040 cites W42533308 @default.
- W2158156040 cites W9441080 @default.
- W2158156040 doi "https://doi.org/10.1016/s0090-4295(00)00936-5" @default.
- W2158156040 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11182341" @default.
- W2158156040 hasPublicationYear "2001" @default.
- W2158156040 type Work @default.
- W2158156040 sameAs 2158156040 @default.
- W2158156040 citedByCount "57" @default.
- W2158156040 countsByYear W21581560402012 @default.
- W2158156040 countsByYear W21581560402014 @default.
- W2158156040 countsByYear W21581560402016 @default.
- W2158156040 countsByYear W21581560402017 @default.
- W2158156040 countsByYear W21581560402018 @default.
- W2158156040 countsByYear W21581560402020 @default.
- W2158156040 countsByYear W21581560402021 @default.
- W2158156040 countsByYear W21581560402022 @default.
- W2158156040 crossrefType "journal-article" @default.
- W2158156040 hasAuthorship W2158156040A5007803051 @default.
- W2158156040 hasAuthorship W2158156040A5075242001 @default.
- W2158156040 hasAuthorship W2158156040A5083235376 @default.
- W2158156040 hasConcept C141071460 @default.
- W2158156040 hasConcept C142724271 @default.
- W2158156040 hasConcept C204787440 @default.
- W2158156040 hasConcept C27081682 @default.
- W2158156040 hasConcept C2777050469 @default.
- W2158156040 hasConcept C2777786686 @default.
- W2158156040 hasConcept C2779121184 @default.
- W2158156040 hasConcept C2779929075 @default.
- W2158156040 hasConcept C42219234 @default.
- W2158156040 hasConcept C71924100 @default.
- W2158156040 hasConceptScore W2158156040C141071460 @default.
- W2158156040 hasConceptScore W2158156040C142724271 @default.
- W2158156040 hasConceptScore W2158156040C204787440 @default.
- W2158156040 hasConceptScore W2158156040C27081682 @default.
- W2158156040 hasConceptScore W2158156040C2777050469 @default.
- W2158156040 hasConceptScore W2158156040C2777786686 @default.
- W2158156040 hasConceptScore W2158156040C2779121184 @default.
- W2158156040 hasConceptScore W2158156040C2779929075 @default.
- W2158156040 hasConceptScore W2158156040C42219234 @default.
- W2158156040 hasConceptScore W2158156040C71924100 @default.
- W2158156040 hasIssue "2" @default.
- W2158156040 hasLocation W21581560401 @default.
- W2158156040 hasLocation W21581560402 @default.
- W2158156040 hasOpenAccess W2158156040 @default.
- W2158156040 hasPrimaryLocation W21581560401 @default.
- W2158156040 hasRelatedWork W1571267551 @default.
- W2158156040 hasRelatedWork W1963931039 @default.
- W2158156040 hasRelatedWork W1967416111 @default.
- W2158156040 hasRelatedWork W1983155011 @default.
- W2158156040 hasRelatedWork W2073008339 @default.
- W2158156040 hasRelatedWork W2118892961 @default.
- W2158156040 hasRelatedWork W2158156040 @default.
- W2158156040 hasRelatedWork W2206444270 @default.
- W2158156040 hasRelatedWork W2256901966 @default.
- W2158156040 hasRelatedWork W250580358 @default.
- W2158156040 hasVolume "57" @default.
- W2158156040 isParatext "false" @default.
- W2158156040 isRetracted "false" @default.
- W2158156040 magId "2158156040" @default.
- W2158156040 workType "article" @default.